Opdivo (nivolumab) developers Ono Pharmaceutical (TYO: 4528) and Bristol-Myers Squibb (NYSE: BMY) have scored positive results for the therapy in the Phase III CheckMate-078 trial.
The study compares the flagship checkpoint inhibitor with the chemotherapeutic docetaxel in a predominantly Chinese population with previously treated advanced non-small cell lung cancer (NSCLC).
Opdivo showed a statistically-significant benefit on the primary endpoint of overall survival, regardless of PD-L1 expression or tumor histology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze